News Alert: Sinobiopharma Inc. (
SNBP) - Zacks Equity Research Initiates Coverage on Sinobiopharma with Outperform Rating and Six Month Price Target of $0.80" (See Full Story Below) CLICK HERE to Download Zacks Research Report Sinobiopharma Inc. (OTCBB:
SNBP) Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM218&N6&L05&F=T Breaking
SNBP News:
November 19 - Zacks Equity Research Initiates Coverage on Sinobiopharma Zacks Equity Research has initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin Board:
SNBP) with an Outperform and six month target price of $0.80. Jiangsu, China-based
SNBP, known domestically as Dong Ying Pharmaceutical Co. Ltd., is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products. The company focuses primarily on the development of anesthesia-assisted agents as well as antibiotics for penicillin-allergic patients and cardiovascular-related products related to high blood pressure (commercial in October 2009). KuTai,
SNBP`s flagship product is a first-to-market Cisatracurium Besylate injectable that serves as a low cost skeletal muscle relaxant used during pre-surgical and surgical procedures. The company holds five patents in Chiral Pharmaceutical Ingredient Synthesis and Purification, and Molecular Packaging Formulation (see proprietary technology section) and has the longer-term ability to expand both the breadth of its product line and market share through R&D partnerships with Cornell University, Nanjing University, China Pharmaceutical University, and Nanjing Medical University.
About Zacks Equity Research Founded in 1978 in Chicago, Zacks Investment Research, Inc. is one of the largest independent investment research and consulting firms in the United States. With 30 years of experience, dedicated to providing clients with the highest standards of services, Zacks has become an industry leader in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Zacks provides clients with professional services in the area of investment research, wealth management, and investment consulting. This information is made available through institutional and non-institutional product lines and web sites, as well as Zacks` own websites http://otcpicknews.com/emailmarketer/link.phpM218&N6&L43&F=T , http://otcpicknews.com/emailmarketer/link.phpM218&N6&L44&F=T , and http://otcpicknews.com/emailmarketer/link.phpM218&N6&L45&F=T ..
Company Overview Sinobiopharma Inc. is an emerging, fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world`s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company`s current therapeutic focus is on anaesthesia-assisted agents and cardiovascular drugs. Founded in 2004, Sinobiopharma employs more than 80 people at its corporate office and production facility in Nantong, China.
Sinobiopharma launched its extremely low-cost, Chinese patented new formulation of the pre-surgical skeletal muscle relaxant Cisatracurium Besylate on May 30, 2006. By October 2007, it had captured 80% of the Chinese market and was in use in more than 200 hospitals.
Anesthetics Product Pipeline Cisatracurium besylate Nondepolarizing skeletal muscle relaxant; indicated for inpatients and outpatients as an adjunct to general anesthesia; facilitates tracheal intubation, and provides skeletal muscle relaxation during surgery or mechanical ventilation in the ICU; approved by the
SFDA in 2006.
Rocuronium Nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration; indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Gantacurium chloride New, investigational, non-depolarizing ultra-short acting neuromuscular blocker; used as an adjunct to general anesthesia to enable rapid intubation of patients undergoing surgery.
Cardiovascular Product Pipeline Eplerenone Blocker of aldosterone binding at the mineralocorticoid receptor; indicated for congestive heart failure, post-myocardial infarction and hypertension.
Perindopril Non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor; indicated for stable coronary artery disease hypertension.
Clevidipine butyrate Dihydropyridine calcium channel blocker; indicated for the reduction of blood pressure when oral therapy is not feasible or desirable.
Revenue Forecast Investment Highlights Leadership of CEO, Dr. Lequn Lee Huang a former manager of the Bayer Co., one of the world`s largest pharmaceutical companies Diverse portfolio of marketed products and robust product pipeline Proven track record of product development and commercialization Strong financial management with CFO formerly of JP Morgan Chase and Smith Kline Beecham Patented technology for fast, low-cost synthesis of active pharmaceutical ingredients (API) enhances capability for rapid development of new drugs Proven R&D partners for collaborative drug discovery and established relationships with multinationals for outsourced drug development Nationwide sales and distribution network Patented technology for rapid low cost drug discovery Experienced management with international track record Flagship drug a best seller in China Robust product pipeline and increasingly diversified portfolio R&D Strength Sinobiopharma conducts research and development through Nanjing Su Ji Biotech Research Development Center and in cooperation with the Medicinal Chemistry Research Institute, Nanjing University. Both are located at Nanjing University in Nanjing. The city has emerged as one of China major biotech research and development centres. Sinobiopharma`s R&D team of 18 specialists (out of a total staff of 80) are highly experienced research personnel and medical professionals. They have given the Company a strong intellectual property base with six patents (see table below), primarily in the area of new methods for synthesizing compounds at lower cost, more rapidly and/or with greater ease of use. This strong R&D capacity, coupled with Sinobiopharma`s established links with multinational pharmaceutical companies makes the Company an attractive partner as a contract research organization (CRO).
Growth Strategy Sinobiopharma has a clearly defined strategy to drive short, middle and long term growth. All drug development will leverage the Company`s patented technology for fast, low-cost drug synthesis and new technology for formulation.
In the Short Term, the focus is launching drugs new to the Chinese market.
The Company`s patented synthesis method allows the company to develop new active pharmaceutical ingredients (API) at lower cost and new formulations that generally offer greater convenience in application and efficacy with fewer side effects.
The Middle Term will focus on exporting Active Pharmaceutical Ingredients and Drug Reformulations developed with the Company`s patented technology for the global market.
The Long Term will focus on applying the technology platform to identifying candidate compounds from Traditional Chinese Medicines. Such compounds have proven their safety and efficacy over thousands of years of use. Sinobiopharma will accelerate their discovery, synthesis and formulation for pharmaceutical applications.
Leverage patented technology for fast, low-cost drug synthesis and new drug formulation Short-term focus on launching Me-too/Me-better drugs new to the Chinese market Medium-term focus on exporting APIs and drug reformulations Long-term focus on applying the technology platform to identify candidate compounds from Traditional Chinese Medicines, Me-new Future Chinese Teva (Israel) Competitive Advantages Expanding in fast-growing Chinese healthcare market Proprietary technology enables low cost, high quality API and innovative formulations for unstable drugs Experience with Chinese FDA expedites fast approval of first-to-market (FTM) drugs FTM drugs get higher price points and exclusivity Integrated marketing and distribution support higher profit Government support includes no-interest loan, tax advantages for five years, and high-tech cooperation benefits Sales and Distribution Nationwide Distribution Network Sinobiopharma has an established a nationwide sales and marketing network that distributes its products in 30 provinces and key major cities throughout China. The Company intends to expand its sales and marketing infrastructure to meet China`s rapidly growing demand for safer, lower-cost, higher-efficacy drugs.
Chinese Pharmaceutical Market Growing at Record Levels Sinobiopharma is expanding in one of the world`s largest and fastest growing markets. The Chinese pharmaceutical market is among the world`s largest, ranking ninth in both terms of volume and dollar value, at $9.8 billion in 2005. (
MIDAS Sales Data, IMS Health, March 2006).
It is also one of the world`s fastest growing. From 2001 to 2005 the Chinese pharmaceutical industry`s compound annual growth rate (
CAGR) was 21%, almost triple the 8%, the global average. The industry is expected to continue this rapid growth, with IMS Health projecting China to have the world`s fifth largest market by 2010.
Other Recent
SNBP News:
November 16 - Sinobiopharma has Production Rights to 23 Drugs Listed in China`s National Essential Drugs List All Drugs on List to be Covered by Basic Government Insurance That Will Cover 90 Percent of China`s Population Sinobiopharma, Inc. (OTCBB:
SNBP) is pleased to announce that 23 generic drugs for which the Company has production rights are listed in China`s National Essential Drugs List, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China.
According to the Chinese government`s healthcare reform plan, 90 percent of China`s citizens will be covered by a universal healthcare system by the year 2010. Under the plan, drugs on the National Essential Drugs List (the "List") will be purchased by various levels of government first, then distributed to medical facilities. All drugs on the List will be covered by the basic insurance plan supported by the government. The plan also calls for medical facilities to be upgraded, which includes the construction of 30,000 new hospitals, clinics and care centers across China.
"While Sinobiopharma is primarily focused on the development, production and distribution of "me-too/me-better" branded new or generic drugs with high margins, the inclusion of 23 generic drugs for which the Company owns production rights on the National Essential Drugs List, will enable us to increase both sales and margins," said Dr. Lequn Lee Huang, Sinobiopharma President and CEO. "We expect that this new advantage in the marketplace will also enable the Company to enhance our ability to improve return on investment for shareholders in 2010." About Sinobiopharma Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world`s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company`s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
Sinobiopharma Inc.
2 Huangpu Road, Nanjing,Jiangsu Province 210000, People`s Republic of China Tel:86.25.8622.8290 Fax:86.25.8320.2848 Website:
www.sinobiopharma.com OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the SEC) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
To view our full disclaimer go to:
http://otcpicknews.com/emailmarketer/link.phpM218&N6&L4&F=T Disclosure: OTCPicks has been compensated five thousand dollars from a third party for a one week
SNBP advertising and promotional program.
Previously OTCPicks.com has been compensated three thousand dollars by a third party (WFWS Consulting) for
SNBP advertising and promotional coverage back in May, 2009.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking
information on smallcap and microcap companies. The web site features
companies in Profile Campaigns, Executive Interviews and Profile
Research Reports authored by our financial writers. We publish a daily
Newsletter to subscribers, and we publish our Daily Market Movers
Digest which is sent out on the M2 Presswire several times daily
highlighting hot OTC and OTCBB stocks. To feature a company on our web
site or in our daily Newsletter or Market Mover's Digest, please
contact our publisher, Brian Dean at 972-546-3740, or via email at
publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails
unless you can afford to lose your entire investment. This disclaimer
is to be read and fully understood before using our site, or joining
our email list. PLEASE NOTE: The OTCPicks.com employees are NOT
Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you
agree to hold OTCPicks.com, its operators owners and employees harmless
and to completely release them from any and all liability due to any
and all loss (monetary or otherwise), damage (monetary or otherwise),
or injury (monetary or otherwise) that you may incur. Neither the
information presented nor any statement or expression of opinion, or
any other matter herein, directly or indirectly constitutes a
representation by the publisher nor a solicitation of the purchase or
sale of any securities. OTCPicks.com has not been compensated by any of
the companies covered in this release. For a complete list of
disclosures go to http://www.otcpicks.com/disclosure_details.php . The
information contained herein is based on sources which we believe to be
reliable but is not guaranteed by us as being accurate and does not
purport to be a complete statement or summary of the available data.
The owner, publisher, editor and their associates are not responsible
for errors and omissions. They may from time to time have a position in
the securities mentioned herein and may increase or decrease such
positions without notice. Any opinions expressed are subject to change
without notice. OTCPicks.com encourages readers and investors to
supplement the information in these reports with independent research
and other professional advice. All information on featured companies is
provided by the companies profiled, or is available from public sources
and OTCPicks.com makes no representations, warranties or guarantees as
to the accuracy or completeness of the disclosure by the profiled
companies or the information contained herein. OTCPicks.com and its
affiliates are not registered investment advisors or a broker dealers.
OTCPicks.com has been advised that the investments in companies
profiled are considered to be high risk and use of the information
provided is at the investor's sole risk. OTCPicks.com also advises that
the purchase of such high risk securities may result in the loss of
some or all of the investment. Investors should not rely solely on the
information presented. Rather, investors should use the information
provided by the profiled companies as a starting point for doing
additional independent research on the profiled companies in order to
allow the investor to form his or her own opinion regarding investing
in the profiled companies. Factual statements made by the profiled
companies are made as of the date stated and are subject to change
without notice. Investing in micro-cap securities is highly speculative
and carries an extremely high degree of risk. It is possible that an
investor`s entire investment may be lost or impaired due to the
speculative nature of the companies profiled. OTCPicks.com makes no
recommendation that the securities of the companies profiled should be
purchased, sold or held by individuals or entities that learn of the
profiled companies through OTCPicks.com. OTCPicks.com owners may or may
not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information
within the meaning of Section 27A of the Securities Act of 1993 and
Section 21E of the Securities Exchange Act of 1934 including statements
regarding expected continual growth of the company and the value of its
securities. In accordance with the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995 it is hereby noted
that statements contained herein that look forward in time which
include everything other than historical information, involve risk and
uncertainties that may affect the company's actual results of
operation. Factors that could cause actual results to differ include
the size and growth of the market for the company's products, the
company`s ability to fund its capital requirements in the near term and
in the long term, pricing pressures, unforeseen and/or unexpected
circumstances in happenings, pricing pressures, etc. Investing in
securities is speculative and carries risk. Past performance does not
guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party
websites or access to third party content. OTCPicks.com does not
control, endorse, or guarantee content found in such sites. You agree
that OTCPicks.com is not responsible for any content, associated links,
resources, or services associated with a third party site. You further
agree that OTCPicks.com shall not be liable for any loss or damage of
any sort associated with your use of third party content. Links and
access to these sites are provided for your convenience only.
Disclaimer: http://www.otcpicks.com/disclaimer.htm
Disclosure Details: http://www.otcpicks.com/disclosure-details.htm
CONTACT: Brian Dean, Publisher, OTCPicks.com
Tel: +1 972 546 3740
EMail : publisher@otcpicks.com
See OTC Picks's website for full disclaimer. OTC Picks may have received compensation for stock picks.
Home
